← Back to Home

Seeking More Clues in Rare Disease Diagnosis: Ambry Launches Pangenome-Based Whole-Genome Testing

From identifying DNA variants and adding RNA functional evidence to reinterpreting results as knowledge advances, Ambry has incorporated three approaches into its rare disease testing services. How many additional patients this combination can provide answers for still requires direct validation.

By SURL BioNews

For families affected by rare diseases who have spent years searching for a cause, a negative genetic test report may simply mean that the trail of clues has temporarily gone cold. Some disease-causing variants go unidentified; others are found but lack sufficient evidence for interpretation. On October 13, Ambry Genetics announced the launch of GenomeNext and GenomeReveal, seeking to carry this diagnostic process forward through three stages: detection, functional interpretation, and subsequent reanalysis.

The new services from this wholly owned subsidiary of Tempus AI center on GenomeNext whole-genome sequencing; the product page indicates that ordering is already available through AmbryPort. The analysis covers nuclear and mitochondrial genetic variants, including copy number and structural variants. Certain more specialized changes are also included, such as SMN1 and SMN2 copy numbers and specific repeat expansions in FMR1, DMPK, and PHOX2B, but this does not mean that all repeat expansion disorders are covered.

One design feature is the use of a pangenome reference, allowing the genetic map used to compare patient sequences to represent broader human diversity. Ambry says the aim is to improve variant detection in patients of different ancestral backgrounds. This claim addresses the longstanding issue of representation in genetic testing; however, the announcement did not provide prospective comparisons of the new services’ performance across ancestry groups.

Once a DNA variant is identified, the next question is whether it actually affects gene function. According to the product page, GenomeReveal adds RNA analysis when whole-genome analysis identifies clinically relevant variants requiring functional evidence, examining clues such as splicing or gene expression. This is not a fixed analytical step initiated for every case, but an approach used to strengthen the interpretation of specific findings; the associated testing workflow requires DNA specimens preserved in EDTA and RNA specimens preserved in PAXgene.

Another layer of the design incorporates time into diagnosis. Through the Patient for Life program included in the services, the laboratory proactively reanalyzes data as new knowledge emerges about gene–disease associations, giving initially negative results or findings of uncertain significance an opportunity for new interpretations. If the biological parents can participate and consent, Ambry also recommends trio testing of the patient and both parents, using information on inheritance to aid interpretation.

The research currently supporting these approaches must be understood separately from the overall performance of the new products. The RNA evidence cited by the company comes from a 2024 hereditary cancer testing study in *JAMA Oncology*; the reported finding that approximately 5% of negative or uncertain cases became positive after reanalysis comes from a 2025 exome sequencing study in *Genetics in Medicine*. RTTNews also attributed this figure to data cited by Ambry. The two studies support individual methods and cannot be taken directly as the rare disease diagnostic yield of the integrated GenomeNext and GenomeReveal services.

The concrete advance in this launch is the inclusion of broader sequence comparison, selective RNA evidence, and ongoing reanalysis within a single testing service. Whether it can shorten the time patients spend searching for a cause, and how many additional diagnoses it can provide in cases unresolved by existing testing, still requires clinical data on the full workflow. The company announcement also identifies the expected benefits as forward-looking statements; for patients, the availability of a service for ordering and a demonstrated degree of improvement in diagnosis remain two different stages.

References

  1. Ambry Genetics / Business Wire via Finviz
  2. Ambry Genetics
  3. Ambry Genetics / Business Wire via FinancialContent
  4. RTTNews